Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- Clinical Study Details
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
-
Cancer -
Non Hodgkin Lymphoma (NHL) -
Follicular Lymphoma -
Leukemia -
Chronic Lymphocytic Leukemia
- For Medical Professional
-
Download -
Basic Details
Sponsor
Hoffmann-La Roche
Phase
N/A
Study Identifier
NCT03374137, ML30074
Condition
Chronic Lymphocytic Leukemia, Follicular Lymphoma
Official Title
Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients
Study Summary
This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.
Eligibility Criteria
All
≥ 18 Years
No
Inclusion Criteria
- Administered obinutuzumab under the approved indications in Korea at investigator's discretion
- Previously untreated with obinutuzumab
Exclusion Criteria
- Out-of locally approved indications, dosage, and administration
- Pregnant women, breastfeeding women
- Hepatic disease
- Participate in other clinical trials
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com